+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tapentadol Market - Global Forecast to 2030- Product Image
Tapentadol Market - Global Forecast to 2030- Product Image
New

Tapentadol Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082595
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tapentadol Market grew from USD 4.10 billion in 2024 to USD 4.38 billion in 2025. It is expected to continue growing at a CAGR of 6.41%, reaching USD 5.96 billion by 2030.

Tapentadol has emerged as a pivotal analgesic agent, distinguished by its dual mechanism of action combining µ-opioid receptor agonism with norepinephrine reuptake inhibition. This unique profile offers superior efficacy in managing both nociceptive and neuropathic pain, positioning it as a vital alternative to traditional opioid monotherapies. Recent years have witnessed growing adoption across diverse patient populations, driven by an escalating global burden of chronic pain conditions and heightened scrutiny of opioid safety.

Against the backdrop of evolving regulatory landscapes, shifting reimbursement policies, and intensified scrutiny on opioid prescribing, the market for tapentadol is entering a critical inflection point. Market participants must navigate complex supply chain dynamics, emerging trade barriers, and competitive pressures from generics and novel non-opioid analgesics. This executive summary synthesizes key market developments, regulatory catalysts, and strategic shifts shaping the future of tapentadol. It provides decision-makers with actionable insights into emerging growth drivers, risk factors, and partnership opportunities, serving as a foundational guide for executives, investors, and healthcare stakeholders seeking to optimize their strategic positioning in this dynamic market.

Transformative Shifts in the Pain Management Landscape

The global analgesics landscape is undergoing transformative shifts as both industry and healthcare systems adapt to new paradigms in pain care. First, patient-centric models emphasizing personalized treatment regimens are reshaping prescribing patterns; clinicians are increasingly leveraging tapentadol’s dual mechanism to tailor therapy for neuropathic and chronic pain populations. Second, the surge in digital health tools, from telemedicine consultations to remote patient monitoring, is streamlining pain assessment and adherence, accelerating market penetration of innovative analgesics.

Meanwhile, the competitive landscape is evolving through consolidation and strategic alliances. Leading pharmaceutical players are forging partnerships with contract development and manufacturing organizations to enhance capacity and optimize cost structures. At the same time, generic entrants are intensifying pricing pressure, compelling innovators to differentiate through formulation advancements such as extended-release injections and abuse-deterrent technology. Regulatory bodies are also tightening opioid stewardship guidelines, catalyzing shifts toward non-opioid and dual-mechanism therapies. This confluence of patient demand, technological innovation, and regulatory oversight is fundamentally redefining market opportunities for tapentadol.

Cumulative Impact of United States Tariffs 2025

The introduction of new United States tariffs in 2025 has introduced a complex array of challenges for tapentadol supply chains and cost structures. Tariffs targeting active pharmaceutical ingredients imported from key manufacturing hubs in Asia have elevated raw material expenses by up to 12 percent in some cases, forcing producers to reevaluate sourcing strategies and absorb or pass through incremental costs. These levy increases have generated ripple effects across distribution channels, prompting longer lead times as suppliers seek alternative low-tariff suppliers or invest in domestic production capacity.

In parallel, the tariffs have triggered strategic inventory management initiatives, with manufacturers stockpiling critical components to buffer against further trade disputes. While this approach mitigates immediate supply disruptions, it ties up working capital and heightens warehousing costs. Additionally, downstream players-particularly retail pharmacies and hospitals-are negotiating harder on price, amplifying margin pressures. As a result, companies that proactively diversify their supplier base, optimize their global logistics networks, and implement lean inventory practices will be best positioned to navigate the cumulative trade headwinds of 2025 and beyond.

Key Segmentation Insights Across Multiple Dimensions

Segmentation analysis reveals nuanced opportunities across application, end user, formulation type, patient demographics, distribution channel, therapeutic class, manufacturing process, and dosage form. In the application segment, neuropathic pain represents a high-growth domain driven by diabetic neuropathy prevalence and post-herpetic neuralgia incidence, while the acute and chronic pain subcategories within pain management continue to benefit from procedural analgesia and long-term therapy demand. End-user dynamics show hospitals-both private and public-absorbing the bulk of hospital-administered formulations, whereas online pharmacies, encompassing direct-to-consumer platforms and third-party marketplaces, are rapidly expanding due to convenience and digital engagement, and retail pharmacies, including national chains and independent outlets, remain critical channels for immediate-release formulations.

Formulation type segmentation underscores the growing importance of extended-release tablets and injections for inpatient and outpatient settings, contrasted with immediate-release options favored for breakthrough pain episodes. Patient demographic insights indicate that middle-aged, senior, and young adult cohorts within the adult population account for the majority of prescriptions, while pediatric applications-particularly for children-are emerging niche areas requiring specialized dosing strategies. Distribution channels are fragmenting as e-commerce and telemedicine integrate within online sales, complementing traditional hospital pharmacies and retail environments such as supermarkets.

Therapeutic class segmentation highlights a clear bifurcation between non-opioid and opioid analgesics, with acetaminophen and NSAIDs capturing adjunctive therapy roles, and synthetic opioids, including tapentadol, holding a differentiated position due to efficacy and safety advantages. Manufacturing process segmentation emphasizes the need for robust biotech and small molecule synthesis capabilities alongside stringent primary and secondary packaging protocols. Finally, dosage form preferences vary by region and setting, with oral capsules and tablets dominating chronic therapies, and parenteral injections and IV solutions reserved for acute care.

Key Regional Insights Driving Market Dynamics

Regionally, the Americas continue to lead global tapentadol consumption, underpinned by the United States’ advanced reimbursement frameworks, favorable prescribing guidelines for dual-mechanism analgesics, and robust hospital infrastructure. Latin American markets are following closely, with increasing adoption supported by expanding healthcare coverage and local generic production. In Europe, Middle East and Africa, Western Europe’s stringent regulatory standards and growing emphasis on opioid stewardship have propelled tapentadol’s adoption in centers of excellence, while emerging markets in the Middle East and Africa are cultivating demand through improved access programs and public-private partnerships. The Asia-Pacific region presents the most dynamic growth trajectory, led by China and India, where rising disposable incomes, an aging population, and expanding pharmaceutical manufacturing capabilities are catalyzing market expansion. Southeast Asian markets are also witnessing accelerated uptake, driven by government initiatives to strengthen pain management protocols and telemedicine penetration.

Key Company Insights Shaping the Competitive Landscape

A competitive review of leading stakeholders reveals a diverse ecosystem spanning generics specialists, branded innovators, and contract service providers. Apotex Corporation and Arene Life Sciences Limited have leveraged cost-efficient manufacturing footprints to capture share in value segments, while Cadila Pharmaceuticals Ltd. and IPCA Laboratories Ltd. are deepening their pipelines through novel tapentadol formulations and license agreements. Curia Global, Inc. and Manus Aktteva Biopharma LLP stand out as strategic partners, offering end-to-end CDMO capabilities that accelerate time-to-market and de-risk production scaling. Major pharmaceutical corporates such as Johnson & Johnson Services, Inc. and Sun Pharmaceutical Industries Limited drive brand equity through global marketing networks and established distribution channels.

Lupin Laboratories Ltd. and Taj Pharmaceutical Limited are intensifying efforts in emerging markets by tailoring dosing regimens for regional patient profiles, while Physicians Total Care, Inc. and Quality Care Products focus on hospital and retail pharmacy partnerships to optimize formulary access. Tirupati Medicare Ltd and Virupaksha Group are emerging as agile players in the value segment, emphasizing lean supply chains and competitive pricing. Grünenthal GmbH maintains a strong foothold in Europe through proprietary pain management solutions, reinforcing its leadership via targeted research collaborations.

Actionable Recommendations for Industry Leaders

To capitalize on evolving market dynamics, industry leaders should accelerate diversification of raw material sourcing by partnering with multiple API suppliers and exploring near-shoring options to offset tariff risks. Investing in advanced formulation technologies-particularly abuse-deterrent extended-release systems-will differentiate offerings and enhance patient adherence. Strengthening digital engagement through telehealth integration and patient support platforms can drive prescribing loyalty and optimize outcomes. Formulary access strategies should be reinforced via value-based contracting with payers and hospital networks, demonstrating superior clinical and economic benefits. Additionally, forging strategic alliances with CDMOs can streamline scale-up processes and mitigate manufacturing bottlenecks. Finally, targeted investment in real-world evidence studies and pharmacovigilance initiatives will bolster the safety profile and facilitate regulatory approvals across new markets.

Conclusion: Navigating Toward Sustainable Growth

The tapentadol market is at a pivotal juncture, shaped by regulatory evolution, supply chain realignment, and shifting patient expectations. Companies that proactively adapt to tariffs by diversifying suppliers, embrace digital therapeutics, and innovate in formulation will secure sustainable growth. Strategic partnerships with contract manufacturers and payers will optimize cost structures and expand market access, while rigorous evidence generation will underpin future approvals and guideline endorsements. As geographic hotspots emerge in Asia-Pacific and Latin America, tailored regional strategies will unlock incremental opportunities. By aligning product, process, and partnership strategies, stakeholders can navigate uncertainties and realize the full potential of tapentadol as a cornerstone of modern pain management.

Market Segmentation & Coverage

This research report categorizes the Tapentadol Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Neuropathic Pain
    • Diabetic Neuropathy
    • Post-Herpetic Neuralgia
  • Pain Management
    • Acute Pain
    • Chronic Pain
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Online Pharmacies
    • Direct To Consumer
    • Third-Party Marketplaces
  • Retail Pharmacies
    • Chain Pharmacies
    • Independent Pharmacies
  • Extended Release
    • Injection
    • Tablet
  • Immediate Release
    • Injection
    • Tablet
  • Adult
    • Middle Aged
    • Senior
    • Young Adult
  • Pediatric
    • Children
    • Infants
  • Hospital Pharmacies
  • Online Sales
    • E-Commerce
    • Telemedicine
  • Retail Channels
    • Pharmacies
    • Supermarkets
  • Non-Opioid Analgesics
    • Acetaminophen
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Opioid Analgesics
    • Natural Opioids
    • Synthetic Opioids
  • Packaging Process
    • Primary Packaging
    • Secondary Packaging
  • Pharmaceutical Manufacturing
    • Biotech Manufacturing
    • Small Molecule Synthesis
  • Oral Dosage
    • Capsule
    • Tablet
  • Parenteral Dosage
    • Injection
    • IV Solution

This research report categorizes the Tapentadol Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Tapentadol Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Apotex Corporation
  • Arene Life Sciences limited
  • Cadila Pharmaceuticals Ltd.
  • Curia Global, Inc.
  • Grünenthal GmbH
  • IPCA Laboratories Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Laboratories Ltd.
  • Manus Aktteva Biopharma LLP
  • Physicians Total Care, Inc.
  • Quality Care Products
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceutical Limited
  • Tirupati Medicare Ltd
  • Virupaksha Group

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tapentadol Market, by Application
8.1. Introduction
8.2. Neuropathic Pain
8.2.1. Diabetic Neuropathy
8.2.2. Post-Herpetic Neuralgia
8.3. Pain Management
8.3.1. Acute Pain
8.3.2. Chronic Pain
9. Tapentadol Market, by End User
9.1. Introduction
9.2. Hospitals
9.2.1. Private Hospitals
9.2.2. Public Hospitals
9.3. Online Pharmacies
9.3.1. Direct To Consumer
9.3.2. Third-Party Marketplaces
9.4. Retail Pharmacies
9.4.1. Chain Pharmacies
9.4.2. Independent Pharmacies
10. Tapentadol Market, by Formulation Type
10.1. Introduction
10.2. Extended Release
10.2.1. Injection
10.2.2. Tablet
10.3. Immediate Release
10.3.1. Injection
10.3.2. Tablet
11. Tapentadol Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.2.1. Middle Aged
11.2.2. Senior
11.2.3. Young Adult
11.3. Pediatric
11.3.1. Children
11.3.2. Infants
12. Tapentadol Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Sales
12.3.1. E-Commerce
12.3.2. Telemedicine
12.4. Retail Channels
12.4.1. Pharmacies
12.4.2. Supermarkets
13. Tapentadol Market, by Therapeutic Class
13.1. Introduction
13.2. Non-Opioid Analgesics
13.2.1. Acetaminophen
13.2.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.3. Opioid Analgesics
13.3.1. Natural Opioids
13.3.2. Synthetic Opioids
14. Tapentadol Market, by Manufacturing Process
14.1. Introduction
14.2. Packaging Process
14.2.1. Primary Packaging
14.2.2. Secondary Packaging
14.3. Pharmaceutical Manufacturing
14.3.1. Biotech Manufacturing
14.3.2. Small Molecule Synthesis
15. Tapentadol Market, by Dosage Form
15.1. Introduction
15.2. Oral Dosage
15.2.1. Capsule
15.2.2. Tablet
15.3. Parenteral Dosage
15.3.1. Injection
15.3.2. IV Solution
16. Americas Tapentadol Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Tapentadol Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Tapentadol Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Apotex Corporation
19.3.2. Arene Life Sciences limited
19.3.3. Cadila Pharmaceuticals Ltd.
19.3.4. Curia Global, Inc.
19.3.5. Grünenthal GmbH
19.3.6. IPCA Laboratories Ltd.
19.3.7. Johnson & Johnson Services, Inc.
19.3.8. Lupin Laboratories Ltd.
19.3.9. Manus Aktteva Biopharma LLP
19.3.10. Physicians Total Care, Inc.
19.3.11. Quality Care Products
19.3.12. Sun Pharmaceutical Industries Limited
19.3.13. Taj Pharmaceutical Limited
19.3.14. Tirupati Medicare Ltd
19.3.15. Virupaksha Group
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. TAPENTADOL MARKET MULTI-CURRENCY
FIGURE 2. TAPENTADOL MARKET MULTI-LANGUAGE
FIGURE 3. TAPENTADOL MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TAPENTADOL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TAPENTADOL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TAPENTADOL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TAPENTADOL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TAPENTADOL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TAPENTADOL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES TAPENTADOL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES TAPENTADOL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA TAPENTADOL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. TAPENTADOL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. TAPENTADOL MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TAPENTADOL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TAPENTADOL MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TAPENTADOL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TAPENTADOL MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TAPENTADOL MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TAPENTADOL MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TAPENTADOL MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TAPENTADOL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TAPENTADOL MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TAPENTADOL MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TAPENTADOL MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TAPENTADOL MARKET SIZE, BY THIRD-PARTY MARKETPLACES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TAPENTADOL MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TAPENTADOL MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TAPENTADOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TAPENTADOL MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TAPENTADOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TAPENTADOL MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TAPENTADOL MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TAPENTADOL MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TAPENTADOL MARKET SIZE, BY SENIOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TAPENTADOL MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TAPENTADOL MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TAPENTADOL MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TAPENTADOL MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TAPENTADOL MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TAPENTADOL MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TAPENTADOL MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TAPENTADOL MARKET SIZE, BY TELEMEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TAPENTADOL MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TAPENTADOL MARKET SIZE, BY SUPERMARKETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TAPENTADOL MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TAPENTADOL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TAPENTADOL MARKET SIZE, BY NATURAL OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL TAPENTADOL MARKET SIZE, BY SYNTHETIC OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL TAPENTADOL MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL TAPENTADOL MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL TAPENTADOL MARKET SIZE, BY BIOTECH MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL TAPENTADOL MARKET SIZE, BY SMALL MOLECULE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL TAPENTADOL MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL TAPENTADOL MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL TAPENTADOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL TAPENTADOL MARKET SIZE, BY IV SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 160. CANADA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. CANADA TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 162. CANADA TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 163. CANADA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. CANADA TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. CANADA TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. CANADA TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 167. CANADA TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 168. CANADA TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 169. CANADA TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 170. CANADA TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 171. CANADA TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 172. CANADA TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 173. CANADA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. CANADA TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 175. CANADA TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 176. CANADA TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 177. CANADA TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 178. CANADA TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 179. CANADA TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 180. CANADA TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 181. CANADA TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 182. CANADA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 183. CANADA TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 184. CANADA TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 185. MEXICO TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. MEXICO TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 187. MEXICO TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 188. MEXICO TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. MEXICO TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. MEXICO TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 191. MEXICO TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 192. MEXICO TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 193. MEXICO TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 194. MEXICO TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 195. MEXICO TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. MEXICO TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 197. MEXICO TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 198. MEXICO TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. MEXICO TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 203. MEXICO TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 205. MEXICO TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 206. MEXICO TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 207. MEXICO TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 208. MEXICO TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 209. MEXICO TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES TAPENTADOL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC TAPENTADOL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 287. CHINA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. CHINA TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 289. CHINA TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 290. CHINA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. CHINA TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. CHINA TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 293. CHINA TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 294. CHINA TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 295. CHINA TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 296. CHINA TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 297. CHINA TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 298. CHINA TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 299. CHINA TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 300. CHINA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. CHINA TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 302. CHINA TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 303. CHINA TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 304. CHINA TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 305. CHINA TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 306. CHINA TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 307. CHINA TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 308. CHINA TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 309. CHINA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 310. CHINA TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 311. CHINA TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 312. INDIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. INDIA TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 314. INDIA TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 315. INDIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDIA TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 317. INDIA TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 318. INDIA TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 319. INDIA TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 320. INDIA TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 321. INDIA TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 322. INDIA TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 323. INDIA TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 324. INDIA TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 325. INDIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. INDIA TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 327. INDIA TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 328. INDIA TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 329. INDIA TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 330. INDIA TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 331. INDIA TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 332. INDIA TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 333. INDIA TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 334. INDIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 335. INDIA TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 336. INDIA TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 337. INDONESIA TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. INDONESIA TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 339. INDONESIA TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 340. INDONESIA TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. INDONESIA TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 342. INDONESIA TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 343. INDONESIA TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 344. INDONESIA TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 345. INDONESIA TAPENTADOL MARKET SIZE, BY EXTENDED RELEASE, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA TAPENTADOL MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA TAPENTADOL MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA TAPENTADOL MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA TAPENTADOL MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA TAPENTADOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA TAPENTADOL MARKET SIZE, BY ONLINE SALES, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA TAPENTADOL MARKET SIZE, BY RETAIL CHANNELS, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA TAPENTADOL MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA TAPENTADOL MARKET SIZE, BY NON-OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA TAPENTADOL MARKET SIZE, BY OPIOID ANALGESICS, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA TAPENTADOL MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 357. INDONESIA TAPENTADOL MARKET SIZE, BY PACKAGING PROCESS, 2018-2030 (USD MILLION)
TABLE 358. INDONESIA TAPENTADOL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 359. INDONESIA TAPENTADOL MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 360. INDONESIA TAPENTADOL MARKET SIZE, BY ORAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 361. INDONESIA TAPENTADOL MARKET SIZE, BY PARENTERAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 362. JAPAN TAPENTADOL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 363. JAPAN TAPENTADOL MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 364. JAPAN TAPENTADOL MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 365. JAPAN TAPENTADOL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 366. JAPAN TAPENTADOL MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 367. JAPAN TAPENTADOL MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 368. JAPAN TAPENTADOL MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 369. JAPAN TAPENTADOL MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 370. JAPAN TAPENTADOL MARKET SIZE, BY EXTENDED RELEA

Companies Mentioned

  • Apotex Corporation
  • Arene Life Sciences limited
  • Cadila Pharmaceuticals Ltd.
  • Curia Global, Inc.
  • Grünenthal GmbH
  • IPCA Laboratories Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Laboratories Ltd.
  • Manus Aktteva Biopharma LLP
  • Physicians Total Care, Inc.
  • Quality Care Products
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceutical Limited
  • Tirupati Medicare Ltd
  • Virupaksha Group

Methodology

Loading
LOADING...

Related Topics

Related Reports

Tapentadol (CAS 175591-23-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Tapentadol (CAS 175591-23-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 260 Pages
  • Global
From
Pain Management Therapeutics Market by Therapeutics, Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Pain Management Therapeutics Market by Therapeutics, Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Non-opioid Pain Patches Market Size, Share & Trends Analysis Report By Patch Type (Lidocaine, Diclofenac, Methyl Salicylate, Capsaicin, Ketoprofen), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-opioid Pain Patches Market Size, Share & Trends Analysis Report By Patch Type (Lidocaine, Diclofenac, Methyl Salicylate, Capsaicin, Ketoprofen), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From

About the Tapentadol Market

Tapentadol is an opioid analgesic used to treat moderate to severe pain. It is a centrally acting synthetic analgesic with a dual mechanism of action, acting on both the mu-opioid receptor and the norepinephrine reuptake inhibitor. Tapentadol is available in both immediate-release and extended-release formulations. It is used to treat a variety of conditions, including chronic pain, neuropathic pain, and post-operative pain. Tapentadol is generally well-tolerated and has fewer side effects than other opioids. Tapentadol is a relatively new analgesic on the market, but it has been gaining popularity due to its efficacy and safety profile. It is increasingly being used as an alternative to other opioids, such as oxycodone and hydrocodone. Tapentadol is also being used in combination with other analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs), to provide more effective pain relief. Some of the companies in the Tapentadol market include Grünenthal, Endo Pharmaceuticals, and Purdue Pharma. Grünenthal is the manufacturer of the brand name Tapentadol, while Endo Pharmaceuticals and Purdue Pharma both produce generic versions of the drug. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.